UAB To Test Potential COVID-19 Vaccine
By BirminghamWatch
The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.
Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.
The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.
The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”
“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.
Lund said six labs at UAB will work on the project.
Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.
“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.
Seahawks win Super Bowl title, pounding the Patriots 29-13
Seattle's "Dark Side" defense helped Sam Darnold become the first quarterback in the 2018 draft class to win a Super Bowl, to win the franchise's second title.
No, that wasn’t Liam Conejo Ramos in Bad Bunny’s Super Bowl halftime show
A publicist for Bad Bunny confirmed to NPR that the little boy in a blue bunny hat detained by ICE in Minneapolis last month did not participate in the Super Bowl halftime show.
March for Life attendees may have been exposed to measles, DC Health warns
D.C. health officials are contacting people possibly exposed to measles at the March for Life in January, as confirmed cases rise nationwide.
U.S. gave Ukraine and Russia June deadline to reach peace agreement, Zelenskyy says
"The Americans are proposing the parties end the war by the beginning of this summer," Zelenskyy said, speaking to reporters on Friday.
U.K. leader’s chief of staff quits over hiring of Epstein friend as U.S. ambassador
British Prime Minister Keir Starmer's chief of staff resigned Sunday over the furor surrounding the appointment of Peter Mandelson as U.K. ambassador to the U.S. despite his ties to Jeffrey Epstein.
Trump administration lauds plastic surgeons’ statement on trans surgery for minors
A patient who came to regret the top surgery she got as a teen won a $2 million malpractice suit. Then, the American Society of Plastic Surgeons clarified its position that surgery is not recommended for transgender minors.
